ES2844852T3 - Acidos nucleicos bloqueados para capturar genes de fusión - Google Patents
Acidos nucleicos bloqueados para capturar genes de fusión Download PDFInfo
- Publication number
- ES2844852T3 ES2844852T3 ES16828575T ES16828575T ES2844852T3 ES 2844852 T3 ES2844852 T3 ES 2844852T3 ES 16828575 T ES16828575 T ES 16828575T ES 16828575 T ES16828575 T ES 16828575T ES 2844852 T3 ES2844852 T3 ES 2844852T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleotides
- length
- polynucleotide
- probe
- polynucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 241
- 230000004927 fusion Effects 0.000 title claims abstract description 170
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 99
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 80
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 80
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 275
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 260
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 260
- 239000002157 polynucleotide Substances 0.000 claims abstract description 260
- 239000000523 sample Substances 0.000 claims abstract description 227
- 238000000034 method Methods 0.000 claims abstract description 65
- 239000012634 fragment Substances 0.000 claims abstract description 60
- 238000012163 sequencing technique Methods 0.000 claims abstract description 46
- 238000009396 hybridization Methods 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000012472 biological sample Substances 0.000 claims abstract description 9
- 238000002955 isolation Methods 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims description 272
- 206010028980 Neoplasm Diseases 0.000 claims description 80
- 201000011510 cancer Diseases 0.000 claims description 52
- 238000002844 melting Methods 0.000 claims description 20
- 230000008018 melting Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 33
- 102000053602 DNA Human genes 0.000 description 33
- 230000000295 complement effect Effects 0.000 description 26
- 238000001574 biopsy Methods 0.000 description 19
- 230000015654 memory Effects 0.000 description 18
- 238000003860 storage Methods 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000011324 bead Substances 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 101150023956 ALK gene Proteins 0.000 description 7
- 208000035269 cancer or benign tumor Diseases 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 101150068690 eml4 gene Proteins 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- -1 NKRT1 Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 101150006308 botA gene Proteins 0.000 description 3
- 230000008711 chromosomal rearrangement Effects 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 2
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 2
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000022080 low-grade astrocytoma Diseases 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- OTJMDLIUFVHKNU-UHFFFAOYSA-N 2-hydroxy-5-methylidene-3-(piperidin-1-ylamino)cyclopent-2-en-1-one Chemical compound C1C(=C)C(=O)C(O)=C1NN1CCCCC1 OTJMDLIUFVHKNU-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000016613 Autophagy-Related Protein 7 Human genes 0.000 description 1
- 108010092778 Autophagy-Related Protein 7 Proteins 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101100148780 Caenorhabditis elegans sec-16A.1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100035444 Centrosomal protein of 85 kDa-like Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102100026127 Clathrin heavy chain 1 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000737643 Homo sapiens Centrosomal protein of 85 kDa-like Proteins 0.000 description 1
- 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 description 1
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 1
- 101001030284 Homo sapiens Methylthioribulose-1-phosphate dehydratase Proteins 0.000 description 1
- 101000882136 Homo sapiens Protein FAM133B Proteins 0.000 description 1
- 101000805613 Homo sapiens Vacuole membrane protein 1 Proteins 0.000 description 1
- 101000919269 Homo sapiens cAMP-responsive element modulator Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710029140 KIAA1549 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100038593 Methylthioribulose-1-phosphate dehydratase Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038971 Protein FAM133B Human genes 0.000 description 1
- 108090000740 RNA-binding protein EWS Proteins 0.000 description 1
- 102000004229 RNA-binding protein EWS Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000012980 SLC1A2 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100022865 UPF0606 protein KIAA1549 Human genes 0.000 description 1
- 101000803348 Ustilago maydis (strain 521 / FGSC 9021) Virulence-associated membrane protein 1 Proteins 0.000 description 1
- 102100038001 Vacuole membrane protein 1 Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 102100029387 cAMP-responsive element modulator Human genes 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195280P | 2015-07-21 | 2015-07-21 | |
| PCT/US2016/043430 WO2017015513A1 (en) | 2015-07-21 | 2016-07-21 | Locked nucleic acids for capturing fusion genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2844852T3 true ES2844852T3 (es) | 2021-07-22 |
Family
ID=57835293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16828575T Active ES2844852T3 (es) | 2015-07-21 | 2016-07-21 | Acidos nucleicos bloqueados para capturar genes de fusión |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20190071730A9 (https=) |
| EP (2) | EP3325667B1 (https=) |
| JP (1) | JP7074661B2 (https=) |
| CN (1) | CN108138230B (https=) |
| AU (1) | AU2016297096B2 (https=) |
| ES (1) | ES2844852T3 (https=) |
| WO (1) | WO2017015513A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2625288T3 (es) | 2011-04-15 | 2017-07-19 | The Johns Hopkins University | Sistema de secuenciación segura |
| AU2013338393C1 (en) | 2012-10-29 | 2024-07-25 | The Johns Hopkins University | Papanicolaou test for ovarian and endometrial cancers |
| US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| JP6560465B1 (ja) | 2016-09-30 | 2019-08-21 | ガーダント ヘルス， インコーポレイテッド | 無細胞核酸の多重解像度分析のための方法 |
| US9850523B1 (en) | 2016-09-30 | 2017-12-26 | Guardant Health, Inc. | Methods for multi-resolution analysis of cell-free nucleic acids |
| EP3647420B1 (en) * | 2017-06-27 | 2023-08-23 | The University Of Tokyo | Probe and method for detecting transcript resulting from fusion gene and/or exon skipping |
| IL319255A (en) | 2017-08-07 | 2025-04-01 | Univ Johns Hopkins | Methods and materials for cancer assessment and treatment |
| CN108642159B (zh) * | 2018-06-27 | 2022-07-01 | 上海宏滩生物科技有限公司 | 生物芯片检测系统 |
| EP4567131A3 (en) | 2019-01-31 | 2025-09-03 | Guardant Health, Inc. | Compositions and methods for isolating cell-free dna |
| AU2020227672A1 (en) * | 2019-02-25 | 2021-10-07 | Twist Bioscience Corporation | Compositions and methods for next generation sequencing |
| CN110195098A (zh) * | 2019-05-10 | 2019-09-03 | 广州安必平医药科技股份有限公司 | 用于检测braf相关融合基因的探针组、试剂盒及其应用 |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| JP2023513606A (ja) | 2020-02-14 | 2023-03-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 核酸を評価するための方法および材料 |
| US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
| US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
| US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
| CN114958997B (zh) * | 2020-08-31 | 2025-08-22 | 伯科生物科技有限公司 | 用于检测伴侣基因的方法 |
| CN116240268B (zh) * | 2023-02-27 | 2024-04-26 | 北京大学口腔医学院 | 用于检测多个基因重排探针系统 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482834A (en) * | 1982-05-17 | 1996-01-09 | Hahnemann University | Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells |
| US5200313A (en) * | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US20100279890A1 (en) * | 2007-06-27 | 2010-11-04 | Oslo Universitetssykehus Hf | Fusion gene microarray |
| CN101928767A (zh) * | 2009-06-29 | 2010-12-29 | 林新华 | 用于检测慢性粒细胞白血病bcr/abl融合基因的电化学dna生物传感器 |
| EP2494069B1 (en) | 2009-10-30 | 2013-10-02 | Roche Diagniostics GmbH | Method for detecting balanced chromosomal aberrations in a genome |
| WO2011146403A2 (en) * | 2010-05-16 | 2011-11-24 | Reniguard Life Sciences, Inc. | Identification of polymorphic hepatitis b viruses and kras oncogene mutations and clinical use |
| US9562259B2 (en) * | 2011-03-14 | 2017-02-07 | Ventana Medical Systems, Inc. | Method of analyzing chromosomal inversions |
| CA2836836A1 (en) * | 2011-06-01 | 2012-12-06 | Medical Prognosis Institute A/S | Methods and devices for prognosis of cancer relapse |
| ES2578370T3 (es) * | 2011-07-01 | 2016-07-26 | HTG Molecular Diagnostics, Inc | Métodos para detectar fusiones génicas |
| JP2015508644A (ja) * | 2012-02-08 | 2015-03-23 | インサイト ジェネティクス インコーポレイテッド | 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物 |
| WO2013166444A2 (en) * | 2012-05-04 | 2013-11-07 | Boreal Genomics Corp. | Biomarker analysis using scodaphoresis |
| GB2533006B (en) * | 2012-09-04 | 2017-06-07 | Guardant Health Inc | Systems and methods to detect copy number variation |
| CN113337604A (zh) | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
| GB2528205B (en) | 2013-03-15 | 2020-06-03 | Guardant Health Inc | Systems and methods to detect rare mutations and copy number variation |
| CN105378110B (zh) * | 2013-04-17 | 2024-06-25 | 生命技术公司 | 与癌症相关的基因融合体和基因变异体 |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
-
2016
- 2016-07-21 EP EP16828575.7A patent/EP3325667B1/en active Active
- 2016-07-21 JP JP2018502674A patent/JP7074661B2/ja active Active
- 2016-07-21 AU AU2016297096A patent/AU2016297096B2/en active Active
- 2016-07-21 EP EP20206400.2A patent/EP3828292A1/en not_active Withdrawn
- 2016-07-21 CN CN201680054945.9A patent/CN108138230B/zh active Active
- 2016-07-21 ES ES16828575T patent/ES2844852T3/es active Active
- 2016-07-21 WO PCT/US2016/043430 patent/WO2017015513A1/en not_active Ceased
- 2016-07-21 US US15/746,395 patent/US20190071730A9/en not_active Abandoned
-
2017
- 2017-02-13 US US15/431,393 patent/US20170226590A1/en not_active Abandoned
-
2022
- 2022-03-14 US US17/694,423 patent/US20220411877A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7074661B2 (ja) | 2022-05-25 |
| EP3325667B1 (en) | 2020-11-11 |
| US20220411877A1 (en) | 2022-12-29 |
| US20170226590A1 (en) | 2017-08-10 |
| EP3828292A1 (en) | 2021-06-02 |
| WO2017015513A9 (en) | 2018-04-12 |
| AU2016297096A1 (en) | 2018-02-15 |
| AU2016297096A9 (en) | 2019-07-25 |
| CN108138230B (zh) | 2023-03-10 |
| CN108138230A (zh) | 2018-06-08 |
| EP3325667A4 (en) | 2018-12-19 |
| CA2993019A1 (en) | 2017-01-26 |
| EP3325667A1 (en) | 2018-05-30 |
| JP2018524014A (ja) | 2018-08-30 |
| US20190071730A9 (en) | 2019-03-07 |
| US20180195131A1 (en) | 2018-07-12 |
| AU2016297096B2 (en) | 2021-03-18 |
| WO2017015513A1 (en) | 2017-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2844852T3 (es) | Acidos nucleicos bloqueados para capturar genes de fusión | |
| JP7091397B2 (ja) | 合成核酸スパイクイン | |
| US20230141527A1 (en) | Methods for attaching adapters to sample nucleic acids | |
| ES2980689T3 (es) | Métodos para la secuenciación de polinucleótidos libres de células | |
| ES2968333T3 (es) | Métodos para analizar células libres de polinucleótidos | |
| US11384382B2 (en) | Methods of attaching adapters to sample nucleic acids | |
| CA2966577A1 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| ES3031713T3 (en) | Methods, compositions and systems for improving the binding of methylated polynucleotides | |
| JP7546486B2 (ja) | 融合事象によって引き起こされるアライメントエラーを検出および抑制する方法 | |
| WO2024192294A1 (en) | Methods and systems for generating sequencing libraries | |
| CA2993019C (en) | Locked nucleic acids for capturing fusion genes | |
| ES2987661T3 (es) | Métodos de detección de reordenamientos genómicos utilizando ácidos nucleicos libres de células | |
| CA3096261C (en) | Methods for detecting and suppressing alignment errors caused by fusion events | |
| CN111542616A (zh) | 脱氨引起的序列错误的纠正 | |
| CN120500545A (zh) | 肿瘤核酸识别方法 | |
| JP2026501232A (ja) | 無細胞核酸分子のメチル化状態に基づいた相同組換え欠損の検出 |